Literature DB >> 21698473

[Is it possible to compare different studies on efficacy of biologicals in patients with rheumatoid arthritis? : mixed treatment comparison as a new tool for indirect comparison of clinical studies].

K Krüger1, B Hellmich, A Rubbert-Roth, U Müller-Ladner, A Kielhorn.   

Abstract

Head-to-head studies as randomized, double blind clinical studies are the best method for directly comparing the efficacy of different therapeutic strategies. However, at the moment no such studies are available for biological agents in the treatment of patients with rheumatoid arthritis. Therefore it is only possible to compare different treatment strategies by indirect comparisons, for example by adjusted indirect comparison or mixed treatment comparison (MTC). The MTC is accepted by European authorities as supportive clinical evidence. As with the case of meta-analyses the quality of an indirect comparison is determined by the homogeneity of the studies included in the analysis.A short review of eight published indirect comparisons of the efficacy of biological agents in the treatment of patients with rheumatoid arthritis showed that the results with respect to tumor necrosis factor (TNF) blockers are similar and that there are differences in the efficacy of non-TNF biological agents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21698473     DOI: 10.1007/s00393-011-0827-1

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  21 in total

Review 1.  The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis.

Authors:  Gerald Gartlehner; Richard A Hansen; Beth L Jonas; Patricia Thieda; Kathleen N Lohr
Journal:  J Rheumatol       Date:  2006-12       Impact factor: 4.666

2.  [Revision of the recommendations of the Commission on Pharmacotherapy of the German society for Rheumatology. Therapy with tumour necrosis factor blockers for inflammatory rheumatic illnesses].

Authors:  B Manger; H Michels; H G Nüsslein; M Schneider; J Sieper
Journal:  Z Rheumatol       Date:  2007-02       Impact factor: 1.372

3.  The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.

Authors:  R Nixon; N Bansback; A Brennan
Journal:  Rheumatology (Oxford)       Date:  2007-05-03       Impact factor: 7.580

4.  Carbapenems versus other beta-lactams in the treatment of hospitalised patients with infection: a mixed treatment comparison.

Authors:  Steven J Edwards; Mike J Clarke; Sarah Wordsworth; Nicky J Welton
Journal:  Curr Med Res Opin       Date:  2009-01       Impact factor: 2.580

Review 5.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maxime Dougados; Paul Emery; Cecile Gaujoux-Viala; Simone Gorter; Rachel Knevel; Jackie Nam; Monika Schoels; Daniel Aletaha; Maya Buch; Laure Gossec; Tom Huizinga; Johannes W J W Bijlsma; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Cem Gabay; Juan Gomez-Reino; Marios Kouloumas; Tore K Kvien; Emilio Martin-Mola; Iain McInnes; Karel Pavelka; Piet van Riel; Marieke Scholte; David L Scott; Tuulikki Sokka; Guido Valesini; Ronald van Vollenhoven; Kevin L Winthrop; John Wong; Angela Zink; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

6.  A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.

Authors:  Jasvinder A Singh; Robin Christensen; George A Wells; Maria E Suarez-Almazor; Rachelle Buchbinder; Maria Angeles Lopez-Olivo; Elizabeth Tanjong Ghogomu; Peter Tugwell
Journal:  CMAJ       Date:  2009-11-02       Impact factor: 8.262

7.  Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis.

Authors:  Young Ho Lee; Jin Hyun Woo; Young Hee Rho; Seong Jae Choi; Jong Dae Ji; Gwan Gyu Song
Journal:  Rheumatol Int       Date:  2007-10-18       Impact factor: 2.631

Review 8.  A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.

Authors:  K Soares-Weiser; Y Bravo Vergel; S Beynon; G Dunn; M Barbieri; S Duffy; J Geddes; S Gilbody; S Palmer; N Woolacott
Journal:  Health Technol Assess       Date:  2007-10       Impact factor: 4.014

Review 9.  Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews.

Authors:  Fujian Song; Yoon K Loke; Tanya Walsh; Anne-Marie Glenny; Alison J Eastwood; Douglas G Altman
Journal:  BMJ       Date:  2009-04-03

10.  Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.

Authors:  M Schiff; M Keiserman; C Codding; S Songcharoen; A Berman; S Nayiager; C Saldate; T Li; R Aranda; J-C Becker; C Lin; P L N Cornet; M Dougados
Journal:  Ann Rheum Dis       Date:  2007-11-29       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.